|
Oncogenes and Tumor Suppressors
Citations 11-20 of 795 total displayed.
|
Past content
(since May 2000):
|
Potentiation of antileukemic therapies by the dual PI3K/PDK-1 inhibitor, BAG956: effects on BCR-ABL– and mutant FLT3-expressing cells
- Ellen Weisberg, Lolita Banerji, Renee D. Wright, Rosemary Barrett, Arghya Ray, Daisy Moreno, Laurence Catley, Jingrui Jiang, Elizabeth Hall-Meyers, Maira Sauveur-Michel, Richard Stone, Ilene Galinsky, Edward Fox, Andrew L. Kung, and James D. Griffin
Blood 2008; 111: 3723-3734.
[Abstract]
[Full text]
[PDF]
RUNX1 DNA-binding mutations and RUNX1-PRDM16 cryptic fusions in BCR-ABL+ leukemias are frequently associated with secondary trisomy 21 and may contribute to clonal evolution and imatinib resistance
- Catherine Roche-Lestienne, Lauréline Deluche, Sélim Corm, Isabelle Tigaud, Sami Joha, Nathalie Philippe, Sandrine Geffroy, Jean-Luc Laï, Franck-Emmanuel Nicolini, and Claude Preudhomme, on behalf of the Fi-LMC group
Blood 2008; 111: 3735-3741.
[Abstract]
[Full text]
[PDF]
The Jak2V617F oncogene associated with myeloproliferative diseases requires a functional FERM domain for transformation and for expression of the Myc and Pim proto-oncogenes
- Gerlinde Wernig, Jeffrey R. Gonneville, Brian J. Crowley, Margret S. Rodrigues, Mamatha M. Reddy, Heidi E. Hudon, Christoph Walz, Andreas Reiter, Klaus Podar, Yohan Royer, Stefan N. Constantinescu, Michael H. Tomasson, James D. Griffin, D. Gary Gilliland, and Martin Sattler
Blood 2008; 111: 3751-3759.
[Abstract]
[Full text]
[PDF]
Loss of Bcl-x in Ph+ B-ALL increases cellular proliferation and does not inhibit leukemogenesis
- Jason G. Harb, Brenda I. Chyla, and Claudia S. Huettner
Blood 2008; 111: 3760-3769.
[Abstract]
[Full text]
[PDF]
Prospective tracing of MLL-FRYL clone with low MEIS1 expression from emergence during neuroblastoma treatment to diagnosis of myelodysplastic syndrome
- Blaine W. Robinson, Nai-Kong V. Cheung, Christos P. Kolaris, Suresh C. Jhanwar, John K. Choi, Neil Osheroff, and Carolyn A. Felix
Blood 2008; 111: 3802-3812.
[Abstract]
[Full text]
[PDF]
Lyn regulates BCR-ABL and Gab2 tyrosine phosphorylation and c-Cbl protein stability in imatinib-resistant chronic myelogenous leukemia cells
- Ji Wu, Feng Meng, Henry Lu, Ling Kong, William Bornmann, Zhenghong Peng, Moshe Talpaz, and Nicholas J. Donato
Blood 2008; 111: 3821-3829.
[Abstract]
[Full text]
[PDF]
Knock-in of an internal tandem duplication mutation into murine FLT3 confers myeloproliferative disease in a mouse model
- Li Li, Obdulio Piloto, Ho Bao Nguyen, Kathleen Greenberg, Kogo Takamiya, Frederick Racke, David Huso, and Donald Small
Blood 2008; 111: 3849-3858.
[Abstract]
[Full text]
[PDF]
Npm1 is a haploinsufficient suppressor of myeloid and lymphoid malignancies in the mouse
- Paolo Sportoletti, Silvia Grisendi, Samia M. Majid, Ke Cheng, John G. Clohessy, Agnes Viale, Julie Teruya-Feldstein, and Pier Paolo Pandolfi
Blood 2008; 111: 3859-3862.
[Abstract]
[Full text]
[PDF]
Clonal heterogeneity in polycythemia vera patients with JAK2 exon12 and JAK2-V617F mutations
- Sai Li, Robert Kralovics, Gennaro De Libero, Alexandre Theocharides, Heinz Gisslinger, and Radek C. Skoda
Blood 2008; 111: 3863-3866.
[Abstract]
[Full text]
[PDF]
PRDM1 is involved in chemoresistance of T-cell lymphoma and down-regulated by the proteasome inhibitor
- Wei-Li Zhao, Yan-Yan Liu, Qun-Ling Zhang, Li Wang, Christophe Leboeuf, Yi-Wen Zhang, Jie Ma, José-Francisco Garcia, Yong-Ping Song, Jun-Min Li, Zhi-Xiang Shen, Zhu Chen, Anne Janin, and Sai-Juan Chen
Blood 2008; 111: 3867-3871.
[Abstract]
[Full text]
[PDF]
|
|
